GLASGOW, SCOTLAND: In a landmark development for nephrology, the Phase III FIND-CKD trial has demonstrated that finerenone significantly slows kidney function decline and reduces cardiovascular-kidney risks in adults with non-diabetic chronic kidney disease (CKD). The late-breaking results, presented at the 63rd European Renal Association (ERA) Congress and simultaneously published in the New England Journal of Medicine, offer new hope for millions of patients worldwide.

While diabetes is a well-known primary driver of CKD, a substantial portion of the estimated 850 million individuals affected globally develop the condition without it. Historically, these patients have faced a dearth of targeted therapeutic options, leaving them vulnerable to progressive kidney function decline, kidney failure, and severe cardiovascular complications.

The FIND-CKD Trial Design

The FIND-CKD study represents the largest Phase III clinical trial to date focused exclusively on non-diabetic CKD. Enrolling 1,584 participants with diverse underlying etiologies, including hypertension-associated kidney disease and glomerular disorders, the trial randomized patients to receive either finerenone or a placebo, alongside standard-of-care renin-angiotensin system (RAS) inhibitors.

The primary endpoint was the total estimated glomerular filtration rate (eGFR) slope over 32 months. Remarkably, finerenone reduced the annual rate of kidney function decline by 0.7 mL/min/1.73 m² compared to placebo (p<0.001), effectively mitigating the relentless progression of the disease.

“FIND-CKD is a large, rigorously conducted study in non-diabetic CKD across multiple etiologies,” stated Professor Hiddo Lambers Heerspink, lead author and clinical trialist at the University Medical Center Groningen. “The results show that finerenone significantly preserved kidney function and reduced the risk of cardiovascular-kidney outcomes with a consistent effect across prespecified subgroups.”

Cardiovascular-Kidney Outcomes and Safety

Beyond preserving eGFR, finerenone significantly reduced the risk of the key secondary composite cardiovascular-kidney outcome by 23% (hazard ratio 0.77; p=0.043). This composite included kidney failure, a sustained decline in eGFR of at least 57%, hospitalization for heart failure, or cardiovascular death.

Regarding safety, the drug exhibited a tolerable profile consistent with previous trials. While hyperkalemia (elevated potassium levels) occurred more frequently in the finerenone group (17.0% vs. 13.3%), these events rarely led to treatment discontinuation or hospitalization, and acute kidney injury rates remained similar between both cohorts.

As the medical community digests these far-reaching implications, finerenone stands poised to redefine the standard of care for non-diabetic CKD, offering a foundational shift in how clinicians manage this pervasive condition.